Skip to main content

6 Result(s)

within Sumithra J. Mandrekar Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

    Jacob S. Appelbaum, Andrew H. Wei, Sumithra J. Mandrekar, Ing S. Tiong… in Leukemia (2024)

  2. No Access

    Article

    Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

    Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibruti...

    Amy S. Ruppert, Allison M. Booth, Wei Ding, Nancy L. Bartlett… in Leukemia (2021)

  3. No Access

    Article

    Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

    The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance) demonstrated a statistically significant overall survival benefit from the addition of midostaurin to standard frontline chemo...

    Richard A. Larson, Sumithra J. Mandrekar, Lucas J. Huebner, Ben L. Sanford… in Leukemia (2021)

  4. No Access

    Article

    UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

    Purpose We performed a UGT1A1 genotype-guided study to determine the maximum tolerated dose (MTD) and evaluate the toxicities and pharmacokinetics of the combination of capecitabine (CAP)...

    Matthew P. Goetz, Heidi A. McKean, Joel M. Reid… in Investigational New Drugs (2013)

  5. No Access

    Article

    A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin

    The Hsp90-directed anticancer agent 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) is currently undergoing phase I and phase II clinical investigation. Our goal was to develop a simple limited sampling mode...

    Alfred F. Furth, Sumithra J. Mandrekar… in Cancer Chemotherapy and Pharmacology (2008)

  6. No Access

    Article

    A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies

    Bortezomib, a selective inhibitor of the 20S proteasome with activity in a variety of cancers, exhibits sequence-dependent synergistic cytotoxicity with taxanes and platinum agents. Two different treatment sch...

    Cynthia Ma, Sumithra J. Mandrekar… in Cancer Chemotherapy and Pharmacology (2007)